Weed (BUDZ) Cash from Financing Activities (2010 - 2026)
Weed (BUDZ) recorded quarterly Cash from Financing Activities of $29200.0 in Q1 2026, down 80.84% quarter-over-quarter from $152403.0 in Q4 2025, and up 134.64% on a YoY basis from $12444.7 in Q1 2025.
Weed (BUDZ) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Weed's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $29200.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 134.64% year-over-year to $29200.0; the TTM figure through Mar 2026 stood at $183603.0 (down 12.97% YoY), while the FY2025 annual figure was $70103.0, down 75.43% from the prior year.
- Cash from Financing Activities was $29200.0 for Q1 2026 at Weed, down from $152403.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $281344.0 in Q4 2024 to a low of -$530000.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged -$22004.6 across 5 years, with a median of -$10095.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 1975.63% in 2024, then slumped 743.0% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$39981.0 in 2022, then surged by 62.48% to -$15000.0 in 2023, then soared by 1975.63% to $281344.0 in 2024, then sank by 45.83% to $152403.0 in 2025, then sank by 80.84% to $29200.0 in 2026.
- The last three Cash from Financing Activities figures came in at $29200.0 (Q1 2026), $152403.0 (Q4 2025), and $2000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Weed | - | - | - | 29,200.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,200.00 |
| Mar 31, 2026 | 29,200.00 |
| Dec 31, 2025 | 152,403.00 |
| Dec 31, 2025 | 152,403.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -84,300.00 |
| Mar 31, 2025 | -84,300.00 |
| Dec 31, 2024 | 281,344.00 |
| Dec 31, 2024 | 281,344.00 |
| Sep 30, 2024 | 18,925.00 |
| Sep 30, 2024 | 18,925.00 |
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Sep 30, 2023 | -530,000.00 |
| Sep 30, 2023 | -530,000.00 |